Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e121-4. doi: 10.1097/QAI.0000000000000089.

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Author information

1
*Maladies Infectieuses, Brussels, Belgium †Service de Maladies Infectieuses et Tropicales, Hospital Saint-Louis, AP-HP and University of Paris Sorbonne Cité, INSERM, Paris, France ‡Department of Infectious Diseases, Hennepin County Medical Center, Minneapolis, MN §Therapeutic Concepts, Houston, TX ‖Department of Medicine I, University of Bonn, Bonn, Germany ¶Orlando Immunology Center, Orlando, FL #Gilead Sciences, Foster City, CA.
PMID:
24346640
DOI:
10.1097/QAI.0000000000000089
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center